Influenza (flu) is referred to an upper respiratory system contagious disease caused by the influenza virus. Pandemic and seasonal are the two influenza types. Seasonal influenza is sub-divided into three major types, namely A, B, and C influenza. It is mainly transmitted through public places from infected person’s sneeze droplets serving as a disease carrier. As per the Centers for Disease Control and Prevention (CDC), in 2017-2018 symptomatic illnesses of over 49,000,000 and around 79,000 deaths were caused due to Influenza, in the U.S. Pregnant women, geriatrics, pediatrics, low immunity patients having chronic illness, and healthcare professionals are at a high risk of getting infected with influenza.
Request FREE Sample: https://www.coherentmarketinsights.com/insight/request-sample/2414
Global Influenza Diagnostics Market: Dynamics
High influenza prevalence and increasing funding for influenza research diagnostics are key factors, expected to drive growth of the global influenza diagnostics market over the forecast period. As per the World Health Organization (WHO), in 2018, influenza resulted in over 3-5 million severe illness cases and over 290,000-650,000 fatalities worldwide. The National Institute of Allergy and Infectious Disease (NIAID), in 2014, partnered with The National Institutes of Health (NIH) Autoimmune Disease Coordinating Committee (ADCC) supporting The Center of Excellence in Influenza Research and Surveillance (CIERS) for the influenza virus’ better understanding. High number of influenza-prone geriatric population, increasing awareness along with great demand for more efficient and advanced diagnostic tests for influenza are expected to drive the global influenza diagnostics market growth.
Global Influenza Diagnostics Market: Regional insights
North America is expected to hold a dominant position in the global influenza diagnostics market, owing to the CDC’s robust initiatives in order to control the disease spread by actively executing preventive measures along with diagnosing the disease with the help of its National Influenza Surveillance System. Increasing Rapid Diagnostic Tests (RDTs) availability has fueled these implementations further in the U.S.
Asia Pacific is projected to robust growth in the global influenza diagnostics market during the forecast period, due to countries actively participating in preventive measures for countering the influenza incidence. For instance, the CDC in 2014 funded nine cooperative agreements for non-researched-related bilateral influenza in the South-East Asian Region (SEAR), as an initiative for responding to avian, pandemic, and seasonal influenza.
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2414
Global Influenza Diagnostics Market: Competitive landscape
Key players functioning in the global influenza diagnostics market are, Roche Diagnostics, Dickinson and Company, Becton, Thermo Fisher Scientific, Quidel Corporation, Alere, and others. Major market players are focusing on R&D activities for offering efficient and cost-effective diagnostic devices. For instance, Roche, in 2016, received the clearance from U.S. FDA and waiver from Clinical Laboratory Improvement Amendments (CLIA) for its test of cobas Influenza RSV & A/B. The test assists flu RSV and A/B molecular testing of and is used with cobas Liat system.
- Abbott Laboratories, in February 2019, launched reformulated Influenza test – BinaxNow A & B Card 2 rapid. It is an in vitro influenza detecting immunochromatographic assay.
- Eurofins Viracor, Inc., in February 2019, introduced a PCR test for Antiviral Resistance – baloxavir marboxil (XOFLUZA) for detecting H3N2 mutations I38T/M/F.
- Sekisui Diagnostics collaborated with Mesa Biotech, Inc., in 2018 and launched A&B test of Silaris Influenza.
- Abbott Laboratories, in 2018, acquired a service and diagnostic device provider, Alere Inc., which made the diagnostic presence of the company strong in the international market.
- Roche, in 2016, received clearance from the U.S. FDA and waiver from Clinical Laboratory Improvement Amendments (CLIA) for the real-time cobas Influenza A/B & RSV and PCR tests. The test assists flu RSV and A/B molecular testing of and is used with cobas Liat system.
Global Influenza Diagnostics Market: Taxonomy
Based on test type,
Traditional Diagnostic Tests
- Viral Culture
- Rapid Influenza Diagnostic Tests (RIDT)
- Serological Assays
- Direct Fluorescent Antibody (DFA) Tests
Molecular Diagnostic Assays
- Loop-Mediated Isothermal Amplification-Based Assays (LAMP)
- Nucleic Acid Sequence-Based Amplification (NASBA) Tests
- Simple Amplification-Based Assays (SAMBA)
Based on end user,
- Reference Laboratories
- Hospitals & Clinics
Based on region,
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027